A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers
A Phase 1, Open-label Study to Compare the Safety and Pharmacokinetics of Various Formulations of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 or GC4711 in Healthy Volunteers
Sponsor: Galera Therapeutics, Inc.
Listed as NCT03099824, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Galera Therapeutics, Inc., it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Nov 2018 — Oct 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Galera Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .